Catalyst Pharmaceuticals (CPRX) Short-term Investments (2011 - 2022)

Catalyst Pharmaceuticals has reported Short-term Investments for 12 years, with the latest figure at $9.9 million in Q2 2022.

• For the quarter ending Q2 2022, Short-term Investments fell 50.57% year-over-year to $9.9 million; the trailing twelve-month figure through Jun 2022 stood at $9.9 million (down 50.57% YoY), and the FY2021 full-year result was $19.8 million, up 97.4% from the prior year.
• Short-term Investments for Q2 2022 stood at $9.9 million, down from $19.4 million in the prior quarter.
• The five-year high for Short-term Investments was $58.5 million in Q2 2018, with the low at $5.0 million in Q4 2019.
• Historically, Short-term Investments has averaged $26.8 million across 5 years, with a median of $20.0 million in 2021.
• Annual changes were most pronounced in 2018 — Short-term Investments jumped 120.44% — and 2019, when it tumbled 86.44%.
• Catalyst Pharmaceuticals' Short-term Investments stood at $36.9 million in 2018, then plunged by 86.44% to $5.0 million in 2019, then jumped by 100.54% to $10.0 million in 2020, then surged by 97.4% to $19.8 million in 2021, then tumbled by 50.17% to $9.9 million in 2022.
• The last three Short-term Investments figures came in at $9.9 million (Q2 2022), $19.4 million (Q1 2022), and $19.8 million (Q4 2021), per Business Quant data.